Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 5, 2025

Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy?

View original at finance.yahoo.com
Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy? Shares of Bank of America BAC, the second-largest U.S. bank, are poised for another year of double-digit gains, building on its strong 30.5% rally in 2024…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zacks Consensus Estimate for 2026 earnings per share is $4.35

    80% confidence
  • Bank of America targets a 55-59% efficiency ratio

    80% confidence
  • Citigroup expects NII (excluding Markets) to grow 5.5% for 2025

    80% confidence
  • Bank of America carries a Zacks Rank #2 (Buy)

    80% confidence
  • Bank of America targets mid-single-digit CAGR in IB fees and a 50 to 100-bp market share gain over the medium term

    80% confidence
  • JPMorgan anticipates 2025 NII to be $95.8 billion, up more than 3% year over year

    80% confidence
  • Bank of America projects a 5-7% year-over-year increase in NII for 2026, after similar growth this year

    80% confidence
  • Zacks Consensus Estimate for 2025 earnings per share is $3.80

    80% confidence
  • Bank of America aims to achieve earnings growth of almost 12% in the medium term

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com